Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00276536 · ClinicalTrials.gov registry record · Phase 1
Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma
A Phase 1 study, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT00276536 is a Phase 1 study that has completed, run by The Cleveland Clinic. The registered enrollment target is 35 participants.
The verdict
NCT00276536, a Phase 1 study, has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
RATIONALE: Interferon alfa may interfere with the growth of cancer cells and slow the growth of cancer. PURPOSE: This phase I trial is studying the side effects and best dose of interferon alfa in treating patients with stage IV solid tumors, lymphoma, or myeloma.
Interventions
- BIOLOGICAL recombinant interferon alpha-1b
- DRUG IFN
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2001-01 |
| Est. Completion | 2004-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00276536
The ClinicalTrials.gov registry entry for NCT00276536 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which recombinant interferon alpha-1b is the first listed.
NCT00276536 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00276536 about?
NCT00276536 is a clinical study titled "Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma". RATIONALE: Interferon alfa may interfere with the growth of cancer cells and slow the growth of cancer. PURPOSE: This phase I trial is studying the side effects and best dose of interferon alfa in treating patients with stage IV solid tumors, lymphoma, or myeloma.
What is the current status of trial NCT00276536?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2001-01. Estimated completion is 2004-01.
What interventions are being tested in trial NCT00276536?
The interventions under investigation include: recombinant interferon alpha-1b (BIOLOGICAL), IFN (DRUG).
Who is sponsoring clinical trial NCT00276536?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.